🇺🇸 FDA
Patent

US 12410259

CD47 targeted therapies for the treatment of infectious disease

granted A61KA61K2039/505A61K38/1774

Quick answer

US patent 12410259 (CD47 targeted therapies for the treatment of infectious disease) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K38/1774, A61P, A61P31/12